Zydus Cadila gets tentative USFDA to market Leukamia (Lymphoblastic) drug
New Delhi: Drug firm Zydus Cadila has received tentative nod from the US health regulator to market Clofarabine injection, used for treatment of cancer of the white blood cells, in the American market.
"Zydus Cadila has received the tentative approval from the United States Food and Drug Administration (USFDA) to market Clofarabine injection 20mg/20ml vials," Cadila Healthcare said in a BSE filing.
The group now has more than 100 approvals and has filed over 280 abbreviated new drug applications (ANDAs) since the commencement of the filing process in fiscal 2003-04, it added.
Clofarabine is used to treat acute lymphoblastic leukemia (a type of cancer of the white blood cells) of 1-21 years old pediatric patients.
Cadila Healthcare stock closed 2.56 per cent up at Rs 344.10 on BSE.
"Zydus Cadila has received the tentative approval from the United States Food and Drug Administration (USFDA) to market Clofarabine injection 20mg/20ml vials," Cadila Healthcare said in a BSE filing.
The group now has more than 100 approvals and has filed over 280 abbreviated new drug applications (ANDAs) since the commencement of the filing process in fiscal 2003-04, it added.
Clofarabine is used to treat acute lymphoblastic leukemia (a type of cancer of the white blood cells) of 1-21 years old pediatric patients.
Cadila Healthcare stock closed 2.56 per cent up at Rs 344.10 on BSE.
Next Story
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd